Plus   Neg

CELG :FDA Accepts Luspatercept BLA In Myelodysplastic Syndromes,Beta-Thalassemia

Celgene Corp. (CELG) and Acceleron Pharma Inc. (XLRN) said Tuesday that the U.S. Food and Drug Administration accepted Celgene's Biologics License Application or BLA for luspatercept, an investigational erythroid maturation agent, for the treatment of adult patients with very low to intermediate-risk myelodysplastic syndromes or MDS-associated anemia who have ring sideroblasts and require red blood cell or RBC transfusions, and for the treatment of adult patients with beta-thalassemia-associated anemia who require RBC transfusions.

The FDA granted Priority Review to the BLA to evaluate the beta-thalassemia indication and set a target action date of December 4, 2019. The FDA has also set target action date of April 4, 2020 to evaluate the MDS indication.

Celgene believes that luspatercept can play a critical role in treating the anemia associated with these serious blood diseases.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Industrial conglomerate General Electric Co. reported Wednesday a net loss for the third quarter that sharply narrowed from last year. Consolidated revenues rose 5 percent from last year. Both adjusted earnings per share and quarterly revenues topped analysts' expectations. Incredible Fish, Inc. has recalled a small quantity of Incredible Stone Crab Mustard Sauce citing undeclared milk, fish, and eggs allergens, the U.S. Food and Drug Administration announced. The Miami-based wholesale seafood distributor sold the recalled product to a limited number of consumers between October 15 and October 22, 2020, primarily through the company's website. Facebook said Tuesday that it has helped 4.4 million people register to vote for the upcoming U.S. presidential election on November 3, exceeding the tech giant's goal of helping 4 million voters to register. In June, Facebook said it created a new Voting Information Center to provide users with authoritative information, including how and when to vote.
Follow RTT